These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33725335)

  • 1. Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials.
    Hey-Hadavi J; Seekins D; Palmer M; Coffey D; Caminis J; Abdullaev S; Patwardhan M; Tyler H; Raheja R; Stanley AM; Pineda-Salgado L; Bourdet DL; Andrade RJ; Hayashi PH; Dimick-Santos L; Rockey DC; Estilo A
    Drug Saf; 2021 Jun; 44(6):619-634. PubMed ID: 33725335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
    Regev A; Palmer M; Avigan MI; Dimick-Santos L; Treem WR; Marcinak JF; Seekins D; Krishna G; Anania FA; Freston JW; Lewis JH; Sanyal AJ; Chalasani N
    Aliment Pharmacol Ther; 2019 Mar; 49(6):702-713. PubMed ID: 30761572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.
    Rockey DC; Seeff LB; Rochon J; Freston J; Chalasani N; Bonacini M; Fontana RJ; Hayashi PH;
    Hepatology; 2010 Jun; 51(6):2117-26. PubMed ID: 20512999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causality assessment for suspected DILI during clinical phases of drug development.
    Regev A; Seeff LB; Merz M; Ormarsdottir S; Aithal GP; Gallivan J; Watkins PB
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S47-56. PubMed ID: 25352327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.
    Fettiplace A; Marcinak J; Merz M; Zhang HT; Kikuchi L; Regev A; Palmer M; Rockey D; Fontana R; Hayashi PH; Tillmann HL; Di Bisceglie AM; Lewis JH
    Aliment Pharmacol Ther; 2024 Nov; 60(10):1293-1307. PubMed ID: 39300766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
    Palmer M; Regev A; Lindor K; Avigan MI; Dimick-Santos L; Treem W; Marcinak JF; Lewis JH; Anania FA; Seekins D; Shneider BL; Chalasani N
    Aliment Pharmacol Ther; 2020 Jan; 51(1):90-109. PubMed ID: 31762074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
    Palmer M; Kleiner DE; Goodman Z; Brunt E; Avigan MI; Regev A; Hayashi PH; Lewis JH; Mehta R; Harrison SA; Siciliano M; McWherter CA; Vuppalanchi R; Behling C; Miller V; Chalasani N; Sanyal AJ
    Aliment Pharmacol Ther; 2024 Jan; 59(2):201-216. PubMed ID: 37877759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
    Avigan MI; Bjornsson ES; Pasanen M; Cooper C; Andrade RJ; Watkins PB; Lewis JH; Merz M
    Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S19-31. PubMed ID: 25352325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tools for causality assessment in drug-induced liver disease.
    Tillmann HL; Suzuki A; Barnhart HX; Serrano J; Rockey DC
    Curr Opin Gastroenterol; 2019 May; 35(3):183-190. PubMed ID: 30865042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant Medical Comorbidities Are Associated With Lower Causality Scores in Patients Presenting With Suspected Drug-Induced Liver Injury.
    Ghabril M; Gu J; Yoder L; Corbito L; Dakhoul L; Ringel A; Beyer CD; Vuppalanchi R; Barnhart H; Hayashi PH; Chalasani N
    Clin Transl Gastroenterol; 2020 Apr; 11(4):e00141. PubMed ID: 32251016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
    Fontana RJ; Seeff LB; Andrade RJ; Björnsson E; Day CP; Serrano J; Hoofnagle JH
    Hepatology; 2010 Aug; 52(2):730-42. PubMed ID: 20564754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome.
    Naseralallah LM; Aboujabal BA; Geryo NM; Al Boinin A; Al Hattab F; Akbar R; Umer W; Abdul Jabbar L; Danjuma MI
    PLoS One; 2022; 17(9):e0268705. PubMed ID: 36048762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
    Treem WR; Palmer M; Lonjon-Domanec I; Seekins D; Dimick-Santos L; Avigan MI; Marcinak JF; Dash A; Regev A; Maller E; Patwardhan M; Lewis JH; Rockey DC; Di Bisceglie AM; Freston JW; Andrade RJ; Chalasani N
    Drug Saf; 2021 Feb; 44(2):133-165. PubMed ID: 33141341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
    Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
    Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highlights of the drug-induced liver injury literature for 2021.
    Woo SM; Alhaqqan DM; Gildea DT; Patel PA; Cundra LB; Lewis JH
    Expert Rev Gastroenterol Hepatol; 2022 Aug; 16(8):767-785. PubMed ID: 35839342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causality assessment in drug-induced liver injury.
    Hayashi PH
    Semin Liver Dis; 2009 Nov; 29(4):348-56. PubMed ID: 19826968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?
    Shahbaz O; Mahajan S; Lewis JH
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):935-951. PubMed ID: 28772086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Induced Liver Injury: Highlights of the Recent Literature.
    Real M; Barnhill MS; Higley C; Rosenberg J; Lewis JH
    Drug Saf; 2019 Mar; 42(3):365-387. PubMed ID: 30343418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis?
    Teschke R; Eickhoff A; Schulze J
    J Clin Transl Hepatol; 2013 Sep; 1(1):59-74. PubMed ID: 26357608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.